GIP hFc Chimera, Mouse
GIP HFc Chimera, Mouse

The purity of GIP hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC

GIP HFc Chimera, Mouse

GIP hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

GIP hFc Chimera, Mouse

The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.
Z06143
¥63,425.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
GIP (Glu22-Gln85)_x000D_
Accession # P48756		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 34.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-45 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • GIP HFc Chimera, Mouse
    • GIP HFc Chimera, Mouse

    The purity of GIP hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC

  • GIP HFc Chimera, Mouse
    • GIP HFc Chimera, Mouse

    GIP hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.
Synonyms GIP; Incretin

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.